We are a clinical-stage biopharmaceutical company focused on applying our proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases
Last Closing Price
J.P. Morgan,Leerink Partners, BMO Capital Markets, SunTrust Robinson Humphrey
To view the prospectus for InflaRX N.V., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253